



OVAMC Pharmacy Services – Chemotherapy/Hazardous Medication Dilution Chart

****All products should have the following stickers at minimum: BUD, Chemo or Hazardous, REF or Room Temp****

Drug	Vial/Amp (Storage)	Route	Vial Reconstitution	Vial Final Conc.	VIAL BUD	Further Dilution	BUD REF	BUD RT	Infusion Rate	Comments
Abatacept (Orencia) (hazardous-not chemo)	250 mg (REF;PFL)	IV	SWFI 10 mL <i>Use silicone-free syringe provided</i> <i>Direct diluent down side of vial slowly</i>	25 mg/mL	6 hr REF	NS 100 mL Final Conc: ≤10 mg/mL <i>Use silicone-free syringe provided</i>	24 hr	24 hr	30 min	Tubing: 0.2 micron low protein binding in-line filter (10010454)
	125 mg SYR (REF;PFL)	SubQ	N/A	125mg/mL	N/A Discard Unused	N/A			SubQ	Prefilled syringe
ADO-trastuzumab emtansine (Kadcyla) *Not interchangeable with trastuzumab	100 mg 160 mg (REF)	IV	SWFI 100 mg: 5 mL 160 mg: 8 mL <i>Direct diluent down side of vial slowly</i>	20 mg/mL	6 hr REF	NS 250 mL <i>NS ONLY</i>	24 hr	4 hr	Initial dose: 90 min Subsequent: 30 min	DO NOT SHAKE <ul style="list-style-type: none">Use 0.2 micron in-line filterEP: Low
Aldesleukin (IL-2; Proleukin)	22 mill unit (REF;PFL)	IV	SWFI 1.2 mL <i>Direct diluent down side of vial slowly</i>	18 mill unit/mL	6 hr	QS with D5W (50ml) Final Conc: 0.49-1.1 mill units/mL <i>D5W ONLY</i>	48 hr	48 hr	15 min	DO NOT SHAKE <ul style="list-style-type: none">May be given SubQ undilutedPremedication: acetaminophen, H2 antagonistEP:<ul style="list-style-type: none">>12 MU/m2- moderate≤12 MU/m2- low
Alemtuzumab (Lemtrada) (hazardous-not chemo)	12mg (REF;PFL)	IV	Solution	10 mg/mL	6 hr	NS 100mL <i>Alternative: D5W</i>	8 hr	8 hr	4 hrs	DO NOT SHAKE
Arsenic Trioxide (Trisenox)	10 mg amp (RT)	IV	Solution	1 mg/mL	N/A Discard unused	NS 250 mL <i>Alternative: D5W</i>	48 hr	24 hr	First dose: 120 min Subsequent: 60 min (max 4 hr)	<ul style="list-style-type: none">Patient should have baseline and weekly EKG monitoring; hold for QTc>500msIf acute vasomotor reactions occur, may infuse over 4 hoursElectrolyte (K and Mg) abnormalities should be corrected before infusion and K/Mg should be routinely monitoredGoal: K > 4, Mg > 1.8EP: Moderate

PFL=protect from light; BUD=Beyond Use Date; REF=refrigeration; RT=room temperature; SWFI=sterile water for injection (preservative free);
SubQ=subcutaneous; IM=intramuscular; BWFI=bacteriostatic water for injection ; NS=0.9% saline solution; D5W=dextrose 5% in water; LR=lactated ringers solution;
EP: Emetogenic Potential; SDV: single-dose vial; MDV: multi-dose vial; **Use secondary tubing unless otherwise specified.**

*multi-dose vial

vAug2018-BF
Page 1 of 16



OVAMC Pharmacy Services – Chemotherapy/Hazardous Medication Dilution Chart

****All products should have the following stickers at minimum: BUD, Chemo or Hazardous, REF or Room Temp****

Drug	Vial/Amp (Storage)	Route	Vial Reconstitution	Vial Final Conc.	VIAL BUD	Further Dilution	BUD REF	BUD RT	Infusion Rate	Comments
Atezolizumab (Tecentriq) (hazardous-not chemo)	1200mg (REF; PFL)	IV	N/A	60 mg/mL	6 hr	NS 250 mL <i>NS ONLY</i>	24 hr	6 hr	30-60min	DO NOT SHAKE
Azacitidine (Vidaza) <i>Aux labels: Chemo/REF/BUD</i>	100 mg (RT)	IV	SWFI 10 mL	10 mg/mL	1 hr	NS 100 mL <i>Solution will be clear</i> <i>Alternative: LR</i>		1 hr	30 min	Incompatible with D5W EP: Moderate Tubing: secondary (MS3500-15)
		SubQ	<u>COLD</u> SWFI 4 mL <i>SubQ: solution will be cloudy but uniform</i>	25 mg/mL	1 hr RT 22 hr (syringe) REF	N/A	8hr 22 hr (if cold SWFI)	N/A	SubQ	<ul style="list-style-type: none"> SubQ inj: max 3 mL/syringe Rotate injection sites Resuspend by rolling syringe prior to injection EP: Moderate
Belatacept (Nulojix) (hazardous-not chemo)	250 mg (REF;PFL)	IV	10.5 mL SWFI/NS/D5W <i>Use silicone-free syringe provided</i> <i>Direct diluent down side of vial slowly</i>	25 mg/mL	4 hr RT 24 hr REF	NS/D5W Final Conc: 2 - 10 mg/mL <i>Use silicone-free syringe provided</i>	24 hr	4 hr	30 min	DO NOT SHAKE Tubing: 0.2 micron low protein binding in-line filter (10010454)
Bendamustine (Treanda) **LASA**	25mg 100mg (RT;PFL)	IV	SWFI: 25mg: 5mL 100mg: 20mg	5 mg/mL	30 min	NS 500 mL Final Conc: 0.2 - 0.7 mg/mL <i>Alt.: D2.5-1/2NS</i>	24 hr	2 hr	30 min	EP: Moderate Tubing: secondary (MS3500-15)
Bendamustine (Bendeka) **LASA**	100mg* (REF;PFL)	IV	Solution	25mg/mL	MDV: 28d REF	NS 50mL Final Conc: 1.85-5.6mg/mL <i>Alt.:D5W or D2.5-1/2NS</i>	24	6 D5W: 3hrs	10 min	EP: Moderate Tubing: secondary (MS3500-15)
Bevacizumab (Avastin) (hazardous-not chemo)	100 mg 400 mg (REF; PFL)	IV	Solution	25 mg/mL	RT: Discard unused REF:6hr	NS 100 mL <i>NS ONLY</i>	24 hr	8 hr	30 min	DO NOT SHAKE Tubing: secondary (MS3500-15) <ul style="list-style-type: none"> Monitor urine for protein EP: Minimal

PFL=protect from light; BUD=Beyond Use Date; REF=refrigeration; RT=room temperature; SWFI=sterile water for injection (preservative free);

SubQ=subcutaneous; IM=intramuscular; BWFI=bacteriostatic water for injection ; NS=0.9% saline solution; D5W=dextrose 5% in water; LR=lactated ringers solution;

EP: Emetogenic Potential; SDV: single-dose vial; MDV: multi-dose vial; **Use secondary tubing unless otherwise specified.**

*multi-dose vial

vAug2018-BF

Page 2 of 16



OVAMC Pharmacy Services – Chemotherapy/Hazardous Medication Dilution Chart

****All products should have the following stickers at minimum: BUD, Chemo or Hazardous, REF or Room Temp****

Drug	Vial/Amp (Storage)	Route	Vial Reconstitution	Vial Final Conc.	VIAL BUD	Further Dilution	BUD REF	BUD RT	Infusion Rate	Comments
Bleomycin (Blenoxane)	15 unit 30 unit (REF)	IV	15 unit: NS 5 mL 30 unit: NS 10 mL	3 unit/mL	6 hr RT	N/A	14 days	24 hr	IVP over 10 min	<ul style="list-style-type: none"> Pulmonary function tests may be used to monitor pulm toxicity May be administered intrapleurally, see prescribing information Note lifetime maximum EP: Minimal
		IM SubQ	SWFI or NS: 15 unit: 1 mL 30 unit: 2 mL	15 unit/mL		N/A	N/A	24 hr	SubQ or IM	
Bortezomib (Velcade) - criteria	3.5 mg (RT;PFL)	IV	NS 3.5 mL	1 mg/mL	6 hr RT/REF	N/A	N/A	8 hr	IV push over 3-5 sec	<ul style="list-style-type: none"> 72 hrs should elapse between doses For IV and SQ use only; fatal if given by other routes EP: Minimal
		SubQ	**BRAND ONLY** NS 1.4 mL	2.5 mg/mL					SubQ	
Brentuximab vedotin (Adcetris)	50 mg (REF;PFL)	IV	SWFI 10.5 mL <i>Direct diluent down side of vial slowly</i>	5 mg/mL	6 hr REF	NS 100 mL Final Conc: 0.4 - 1.8 mg/mL <i>Alternative: D5W/LR</i>	24 hr	1 hr	30 min	<p>DO NOT SHAKE Tubing: primary (2420-0500)</p> <ul style="list-style-type: none"> Premedication: only if prior infusion reaction (acetaminophen, diphenhydramine +/- corticosteroid) Maximum 180 mg per dose EP: Low
Cabazitaxel (Jevtana)	60 mg (RT)	IV	Use entire contents of supplied diluent. Direct down side of vial. Gently invert for 45 sec.	10 mg/mL	30 min	NS 250 mL Final Conc: 0.1 - 0.26 mg/mL <i>Alternative: D5W</i>	24 hr	8 hr	60 min	<p>DO NOT SHAKE Use 0.2 micron in-line filter Use DEHP-free bags/tubing Discard if crystals seen</p> <ul style="list-style-type: none"> Premedication: diphenhydramine, corticosteroid and H2 antagonist EP: Low
CARBOplatin (Paraplatin)	50 mg* 150 mg* 450 mg* 600 mg* (RT;PFL)	IV	Solution	10 mg/mL	SDV: 6 hr RT MDV: 14 day RT*	D5W 250 mL Final Conc: 0.5 – 4 mg/mL <i>Alternative: NS</i>		8 hr	30 min	<p>Tubing: primary (2420-0500) EP: Moderate</p>

PFL=protect from light; BUD=Beyond Use Date; REF=refrigeration; RT=room temperature; SWFI=sterile water for injection (preservative free);
SubQ=subcutaneous; IM=intramuscular; BWFI=bacteriostatic water for injection ; NS=0.9% saline solution; D5W=dextrose 5% in water; LR=lactated ringers solution;
EP: Emetogenic Potential; SDV: single-dose vial; MDV: multi-dose vial; **Use secondary tubing unless otherwise specified.**

*multi-dose vial



OVAMC Pharmacy Services – Chemotherapy/Hazardous Medication Dilution Chart

****All products should have the following stickers at minimum: BUD, Chemo or Hazardous, REF or Room Temp****

Drug	Vial/Amp (Storage)	Route	Vial Reconstitution	Vial Final Conc.	VIAL BUD	Further Dilution	BUD REF	BUD RT	Infusion Rate	Comments
Carfilzomib (Kyprolis)	60 mg (REF;PFL)	IV	SWFI 29 mL <i>Direct diluent down side of vial slowly Gently swirl x 1 min to dissolve</i>	2 mg/mL	4 hr RT 6 hr REF	D5W 50-100 mL <i>D5W ONLY</i>	24 hr	4 hr	30 min	DO NOT SHAKE Tubing: secondary (MS3500-15) <ul style="list-style-type: none"> Max BSA 2.2m² Pre- and post-hydration for cycle 1 doses and then prn Premedication: dexamethasone for C1 and C2, then prn EP: Low
Cetuximab (Erbix) (hazardous-not chemo)	100 mg 200 mg (REF)	IV	Solution	2 mg/mL	RT: Discard Unused 6 hr REF	DO NOT DILUTE <i>Use sterile, empty container</i>	12 hr	8 hr	Load: 120 min Maint.: 60 min <i>(max rate: 5 mL/min)</i>	DO NOT SHAKE Tubing: 0.2 micron low protein binding in-line filter (10010454) Prime line with saline <ul style="list-style-type: none"> Premedication: diphenhydramine Monitor magnesium EP: Minimal
Cidofovir	375 mg (RT)	IV	Solution	75 mg/mL	6 hrs	NS 100 mL	24 hrs	24 hrs	60 min	Usual dose: 5 mg/kg
Cisplatin (CDDP); Platinol-AQ)	50 mg* 100 mg* 200 mg * (RT;PFL)	IV	Solution	1 mg/mL	7 d* (not PFL) 28 d* (PFL)	NS 500 mL <i>Alternative: D5WNS; D5W1/2NS</i> <i>May be admixed with D5W1/3NS with 37.5 grams of mannitol</i>	72 hr	48 hr	≤ 80 mg/m ² : 60 min > 80 mg/m ² : 90 min	IRRITANT/VESICANT <ul style="list-style-type: none"> For patients with heart failure, administer at a maximum rate of 1mg/min Should be administered with pre- and post-hydration EP: High
Cladribine	10mg (REF;PFL)	IV	Solution	1 mg/mL	6 hrs	NS 250 mL <i>NO D5W</i>	30 hr	24 hr	2 hr	Tubing: 0.2 micron low protein binding in-line filter (10010454)
Cyclophosphamide (Cytoxan) **NOTE: U-LISTED**	500 mg 1 gram 2 gram (RT)	IV	NS or SWFI 500 mg: 25 mL 1 gram: 50 mL 2 gram: 100 mL	20 mg/mL	6 hr RT	NS 250 mL <i>Alt.: D5W, D5WNS, D5WLR, LR, 1/2NS</i>	72 hr D5W: 36hr	24 hr	60 min <i>Rate varies per protocol</i>	Do not use if signs of melting (clear/yellow thick liquid) Tubing: secondary (MS3500-15) EP: >1500mg/m ² : high EP: ≤1500mg/m ² : moderate

PFL=protect from light; BUD=Beyond Use Date; REF=refrigeration; RT=room temperature; SWFI=sterile water for injection (preservative free);

SubQ=subcutaneous; IM=intramuscular; BWFI=bacteriostatic water for injection ; NS=0.9% saline solution; D5W=dextrose 5% in water; LR=lactated ringers solution;

EP: Emetogenic Potential; SDV: single-dose vial; MDV: multi-dose vial; **Use secondary tubing unless otherwise specified.**

*multi-dose vial

vAug2018-BF

Page 4 of 16



OVAMC Pharmacy Services – Chemotherapy/Hazardous Medication Dilution Chart

****All products should have the following stickers at minimum: BUD, Chemo or Hazardous, REF or Room Temp****

Drug	Vial/Amp (Storage)	Route	Vial Reconstitution	Vial Final Conc.	VIAL BUD	Further Dilution	BUD REF	BUD RT	Infusion Rate	Comments
Cyclosporine	250 mg (RT; PFL)	IV	Solution	50 mg/mL	6 hr	NS 100 mL <i>Alternative: D5W</i>		24 hr	2-6 hr	Use DEHP-free bags/device
Cytarabine (Ara-C/Cytosar-U)	100 mg 500 mg 1 gram 2 gram (RT;PFL)	IV	<i>Low dose (<500 mg/m²): BWFI or SWFI</i> <i>High dose (≥500 mg/m²): SWFI only</i> 100 mg: 5 mL 500 mg: 10 mL 1 gram: 10 mL 2 gram: 20 mL	20 mg/mL 50 mg/mL 100 mg/mL 100 mg/mL	6 hr	NS 500 mL		8 hr	≤ 1 gram: 60 min > 1 gram: 120 min <i>May be given as continuous infusion</i>	High dose cytarabine(≥ 500 mg/m²): administer dexamethasone 0.1% eye drops Q6h starting prior to first dose and continuing for 48 hours after last dose EP: >200mg/m2: moderate EP: ≤200mg/m2: minimal
		SubQ IM	Solution	100 mg/mL		N/A	N/A	N/A	SubQ or IM PFL	
Dacarbazine (DTIC; DTIC-dome)	200 mg (REF;PFL)	IV	SWFI 19.7 mL	10 mg/mL	6 hr RT/REF	NS 500 mL <i>Alternative: D5W</i>		24 hr PFL	60 min <i>May be given as continuous infusion</i>	IRRITANT Tubing: secondary (MS3500-15) Decomposition signs: color change to pinkish/reddish EP: High
Daratumumab (Darzalex) (hazardous-not chemo)	100 mg 400 mg (REF;PFL)	IV	Solution	20mg/mL	6 hr REF	NS 500mL	24 hrs	<i>Warm to RT prior to admin</i>	SEE FOOTNOTES Max: 200mg/hr	DO NOT SHAKE Tubing: 0.2 micron low protein binding in-line filter (10010454) <i>Do not use if opaque particles or discolored; Small translucent protein particles are normal</i>
DAUNOrubicin (Cerubidine; Daunomycin) *Not interchangeable with liposomal daunorubicin	20 mg (REF;PFL)	IV	Solution	5 mg/mL	6 hr REF	<i>Dispense in a syringe</i>	48 hr (if powder vial used)	24 hr	IVP over 1-5 min	VESICANT Decomposition sign: color change to purple <ul style="list-style-type: none"> Note lifetime maximum dose Baseline LVEF EP: Moderate

PFL=protect from light; BUD=Beyond Use Date; REF=refrigeration; RT=room temperature; SWFI=sterile water for injection (preservative free);

SubQ=subcutaneous; IM=intramuscular; BWFI=bacteriostatic water for injection ; NS=0.9% saline solution; D5W=dextrose 5% in water; LR=lactated ringers solution;

EP: Emetogenic Potential; SDV: single-dose vial; MDV: multi-dose vial; **Use secondary tubing unless otherwise specified.**

*multi-dose vial

vAug2018-BF

Page 5 of 16



Defining
EXCELLENCE
in the 21st Century

OVAMC Pharmacy Services – Chemotherapy/Hazardous Medication Dilution Chart

****All products should have the following stickers at minimum: BUD, Chemo or Hazardous, REF or Room Temp****

Drug	Vial/Amp (Storage)	Route	Vial Reconstitution	Vial Final Conc.	VIAL BUD	Further Dilution	BUD REF	BUD RT	Infusion Rate	Comments
Decitabine (Dacogen)	50 mg (RT)	IV	SWFI 10 mL	5 mg/mL	N/A Discard unused	NS 100 mL Final Conc: 0.1 – 1 mg/mL <i>Alternative: D5W; LR</i>	7 hr	1 hr	60 min	Doses not started within 15 minutes of preparation should be mixed in COLD solutions EP: Minimal
Dexrazoxane (Zinecard) <i>*Not Chemotherapy*</i>	500 mg (RT;PFL)	IV	Supplied diluent: 50 mL	10 mg/mL	30 min RT 3 hr REF	NS QS to final conc of 1.3 - 3 mg/mL <i>Alternative: D5W</i>	4 hr	1 hr Generic 6 hr Zinecard	10 min <i>Give immediately prior to doxorubicin</i>	Tubing: secondary (MS3500-15)
Dexrazoxane (Totect) <i>*Not Chemotherapy*</i>	500 mg (RT;PFL)	IV	Supplied diluent: 50 mL	10 mg/mL	2 hr RT	NS 1000 mL	4 hr	4 hr	90 min <i>Must begin within 6 hrs of extravasation</i>	<ul style="list-style-type: none"> Used for anthracycline extravasation – 3 day regimen Max doses: <ul style="list-style-type: none"> Day 1 and 2: 2000 mg Day 3: 1000 mg
DOCEtaxel (Taxotere)	20 mg 80 mg 160 mg (RT;PFL)	IV	Solution	20 mg/mL	SDV: 4 hr MDV: 28 d RT;PFL	NS 100-250 mL final conc: 0.3-0.74 mg/mL <i>Alternative: D5W</i>	48 hr	4 hr	60 min	IRRITANT DO NOT SHAKE Use DEHP-free bags/device Tubing: secondary (MS3500-15) <ul style="list-style-type: none"> Premedication: dexamethasone EP: Low
DOXOrubicin (Adriamycin) <i>*Not interchangeable with liposomal doxorubicin</i>	200 mg (REF;PFL)	IV	Solution	2 mg/mL	6 hr PFL	Dispense in a syringe Continuous infusion: Mix in NS 500 mL <i>Alternative: D5W</i>	Cont. Infuse 72hrs PFL	Syringe 24 hr PFL Cont. Infuse: 48hr PFL	IVP over 5-10 min <i>May be given as continuous infusion</i>	VESICANT <ul style="list-style-type: none"> Baseline LVEF Note lifetime maximum dose EP: ≥60mg/m2: High EP: <60mg/m2: Moderate
DOXOrubicin LIPOSOMAL (Doxil) <i>*Not interchangeable with doxorubicin</i>	20 mg 50 mg (REF)	IV	Solution	2 mg/mL	6 hr	D5W ≤90 mg: 250 mL >90 mg: 500 mL <i>D5W ONLY</i>	24 hr		60 min <i>Doses >60 mg: start infusion at 1mg/min X 5 min then titrate to complete the infusion in 1 hr.</i>	IRRITANT DO NOT FILTER Baseline LVEF recommended EP: Low

PFL=protect from light; BUD=Beyond Use Date; REF=refrigeration; RT=room temperature; SWFI=sterile water for injection (preservative free);

*multi-dose vial

vAug2018-BF

SubQ=subcutaneous; IM=intramuscular; BWFI=bacteriostatic water for injection ; NS=0.9% saline solution; D5W=dextrose 5% in water; LR=lactated ringers solution;

Page 6 of 16

EP: Emetogenic Potential; SDV: single-dose vial; MDV: multi-dose vial; **Use secondary tubing unless otherwise specified.**



OVAMC Pharmacy Services – Chemotherapy/Hazardous Medication Dilution Chart

****All products should have the following stickers at minimum: BUD, Chemo or Hazardous, REF or Room Temp****

Drug	Vial/Amp (Storage)	Route	Vial Reconstitution	Vial Final Conc.	VIAL BUD	Further Dilution	BUD REF	BUD RT	Infusion Rate	Comments
Durvalumab (Imfinzi)	120mg 500mg (REF;PFL)	IV	Solution	50mg/mL	Discard unused	NS 100mL Final Conc: 1-15 mg/mL <i>Alt.: D5W</i>	24 hrs	4 hrs	60 min	DO NOT SHAKE Tubing: 0.2 micron low protein binding in-line filter (10010454) EP: minimal
Eculizumab (Soliris) (hazardous-not chemo)	300 mg (REF;PFL)	IV	Solution	10 mg/mL	N/A Discard Unused	NS QS to final conc of 5 mg/mL <i>ADD DRUG FIRST</i> <i>Alt.: D5W; 1/2NS</i>	24 hr PFL		35 min Warm to RT before admin <i>Never exceed 2 hrs duration</i>	Tubing: secondary (MS3500-15) • DO NOT SHAKE • Monitor for at least 1 hr after infusion • Vaccines required at least 2 weeks prior to treatment initiation or prophylaxis needed
Epirubicin (Ellence)	50 mg 200 mg (REF;PFL)	IV	Solution	2 mg/mL	6 hr REF	Dispense in a syringe	24 hr PFL		IVP over 10-15 min <i>Administer into free-flowing IV</i>	VESICANT • Baseline LVEF • Note lifetime maximum dose • EP: >90mg/m2: High • EP: ≤90mg/m2: Moderate
Eribulin Mesylate (Halaven)	1 mg (RT; PFL)	IV	Solution	0.5 mg/mL	4 hr RT 6 hr REF	N/A	N/A	N/A	IVP over 2 – 5 minutes	May dilute in NS 100 mL EP: Low
Etoposide (Toposar; VePesid; VP-16)	100 mg 1000 mg* (RT;PFL)	IV	Solution	20 mg/mL	48 RT MDV: 14 day REF	NS QS to final conc 0.2 - 0.4 mg/mL <i>Alternative: D5W</i>		30 hr	60 min	IRRITANT Use DEHP-free bags/device Tubing: 0.2 micron low protein binding in-line filter (10010454) May be administered CIVI EP: Low
Fludarabine (Fludara)	50 mg (REF)	IV	SWFI 2 mL -or- Solution	25 mg/mL	6 hr	NS 100 mL <i>Alternative: D5W</i>	48 hr	48 hr	30 min	Tubing: secondary (MS3500-15) EP: Minimal
Fluorouracil (5FU; Aduvicol)	500 mg 1 gram 5 gram (RT;PFL)	IV	Solution	50 mg/mL	4 hr PFL	<i>Intermittent:</i> Dispense in syringe <i>CIVI:</i> NS QS to pump conc		72 hr (PFL) 8 days	<i>IVP undiluted over 10-15 min</i> Continuous via pump (range 24-168 hrs)	IRRITANT CIVI: infusion per protocol EP: Low

PFL=protect from light; BUD=Beyond Use Date; REF=refrigeration; RT=room temperature; SWFI=sterile water for injection (preservative free);
SubQ=subcutaneous; IM=intramuscular; BWFI=bacteriostatic water for injection ; NS=0.9% saline solution; D5W=dextrose 5% in water; LR=lactated ringers solution;
EP: Emetogenic Potential; SDV: single-dose vial; MDV: multi-dose vial; **Use secondary tubing unless otherwise specified.**

*multi-dose vial

vAug2018-BF
Page 7 of 16



OVAMC Pharmacy Services – Chemotherapy/Hazardous Medication Dilution Chart

****All products should have the following stickers at minimum: BUD, Chemo or Hazardous, REF or Room Temp****

Drug	Vial/Amp (Storage)	Route	Vial Reconstitution	Vial Final Conc.	VIAL BUD	Further Dilution	BUD REF	BUD RT	Infusion Rate	Comments
Ganciclovir (hazardous-not chemo)	500 mg (RT)	IV	SWFI 10 mL <i>No bacteriostatic saline</i>	50 mg/mL	6 hrs <i>*RT only*</i>	100 mL NS Final Conc: ≤10 mg/mL <i>Alternative: D5W</i>	24 hrs	24 hrs <i>D5W: 12 hrs</i>	60 min	Thrombophlebitis risk Usual dose: 5 mg/kg Max: 1000 mg
Gemcitabine (Gemzar)	200 mg 1 gram 2 gram (RT) Solution: (REF)	IV	NS 200 mg: 5 mL 1 gram: 25 mL 2 gram: 50 mL -or- Solution	38 mg/mL	6 hr RT (REF solution)	NS 250 mL <i>Alternative: D5W</i>		24 hr	30 min 90 min for Doce/Gem protocol	May use intravesically Tubing: secondary (MS3500-15) EP: Low
IDarubicin (Idamycin)	5 mg 10 mg 20 mg (REF;PFL)	IV	Solution	1 mg/mL	6 hr	Dispense undiluted in a syringe	72 hr	48 hr	IVP over 10- 15 min	VESICANT <ul style="list-style-type: none">• Baseline LVEF• Note lifetime maximum dose• EP: Moderate
Ifosfamide (Ifex)	1 gram 3 gram (RT)	IV	SWFI 1 gram: 20 mL 3 gram: 60 mL	50 mg/mL	6 hr REF	NS 500 mL <i>Alternative: D5W</i>	24 hr	24 hr	60 min <i>May be given as continuous infusion</i>	<ul style="list-style-type: none">• Monitor urine for blood• Hydration and mesna required• EP: ≥2g/m2: High• EP:<2g/m2: Moderate
Infliximab (Remicade BRAND)	100mg (REF)	IV	SWFI 10 mL <i>Direct diluent down side of vial</i>	10 mg/mL	3 hr	NS 250 mL		6 hrs	2 hrs	DO NOT SHAKE Begin inf. w/in 3hrs of mixing Use 0.2 micron in-line filter
Infliximab-dyyb (Inflectra - preferred)						Final Conc: 0.4-4 mg/mL				
Interferon alfa-2b (Intron-A)	10 mill unit 18 mill unit 50 mill unit (REF)	IV	Supplied diluent: 1 mL	Varies	6 hr REF	NS 100 mL Final Conc: ≥10 mill unit/100mL <i>Alternative: LR</i>	Per package insert (≤ 24 hrs REF)		20 min	Premix vials <u>NOT</u> recommended for IV admin Ophthalmic solution: 14 days EP: ≥10 million units/m²: Moderate >5 - <10 million units/m²: Low ≤ 5million/units/m²: Minimal
		SubQ IM				N/A	N/A	N/A	IM or SubQ	

PFL=protect from light; BUD=Beyond Use Date; REF=refrigeration; RT=room temperature; SWFI=sterile water for injection (preservative free);
SubQ=subcutaneous; IM=intramuscular; BWFI=bacteriostatic water for injection ; NS=0.9% saline solution; D5W=dextrose 5% in water; LR=lactated ringers solution;
EP: Emetogenic Potential; SDV: single-dose vial; MDV: multi-dose vial; **Use secondary tubing unless otherwise specified.**

*multi-dose vial

vAug2018-BF
Page 8 of 16



OVAMC Pharmacy Services – Chemotherapy/Hazardous Medication Dilution Chart

****All products should have the following stickers at minimum: BUD, Chemo or Hazardous, REF or Room Temp****

Drug	Vial/Amp (Storage)	Route	Vial Reconstitution	Vial Final Conc.	VIAL BUD	Further Dilution	BUD REF	BUD RT	Infusion Rate	Comments
Ipilimumab (Yervoy)	50 mg 200 mg (REF;PFL)	IV	Solution <i>Warm vials to RT for 5 min prior to admixing</i>	5 mg/mL	N/A Discard Unused	NS QS to final conc: 1-2 mg/mL <i>Alternative: D5W</i>	24 hr	24 hr	90 min	DO NOT SHAKE Tubing: 0.2 micron low protein binding in-line filter (10010454) • All 4 doses should be administered within 16 weeks • EP: Minimal
Irinotecan (Camptosar; CPT-11)	40 mg 100 mg 300 mg (RT;PFL)	IV	Solution	20 mg/mL	6 hr	D5W 500 mL Final Conc: 0.12–2.8 mg/mL <i>Alternative: NS</i>	48 hr	24 hr NS: RT only	90 min	NS: do not refrigerate Tubing: secondary (MS3500-15) • Atropine may be administered IVP as a premed or as treatment for acute onset diarrhea. • EP: Moderate
Methotrexate INTRAMUSCULAR <i>Ectopic Pregnancy</i>	50 mg 100 mg 250 mg 1 gram (RT;PFL)	IM	Solution	25 mg/mL	6 hr PFL	N/A	N/A	N/A	IM ONLY	Dose = 50 mg/m ² EP: Minimal
Methotrexate (Trexall; MTX) INTRAVENOUS	Powder: 1 gram (RT;PFL)	IV	NS 19.4 mL	50 mg/mL	6 hr PFL	NS ≤100 mg: 100 mL 101-1000mg: 250 mL >1000 mg: 500 mL Continuous Infusion: NS 1000 mL <i>Alternative: D5W</i>	72 hr	30 hr	**Check Protocol** ≤100 mg: 15 min 101-1000 mg: 2 hr > 1000 mg: 4 hr	Max syringe volume: 22.5 mL in 30 mL syringe Higher methotrexate doses • maintenance of urine pH > 7 helps prevent renal dysfunction • Start after at least 6 hrs of prehydration when urine pH ≥ 7 • leucovorin rescue should be used EP: • ≥250mg/m ² : Moderate • >50mg/m ² <250mg/m ² : Low • ≤50mg/m ² : Minimal
	Solution: 50 mg 100 mg 250 mg 1 gram (RT;PFL)		Solution	25 mg/mL						

PFL=protect from light; BUD=Beyond Use Date; REF=refrigeration; RT=room temperature; SWFI=sterile water for injection (preservative free);

SubQ=subcutaneous; IM=intramuscular; BWFI=bacteriostatic water for injection ; NS=0.9% saline solution; D5W=dextrose 5% in water; LR=lactated ringers solution;

EP: Emetogenic Potential; SDV: single-dose vial; MDV: multi-dose vial; **Use secondary tubing unless otherwise specified.**

*multi-dose vial

vAug2018-BF

Page 9 of 16



OVAMC Pharmacy Services – Chemotherapy/Hazardous Medication Dilution Chart

****All products should have the following stickers at minimum: BUD, Chemo or Hazardous, REF or Room Temp****

Drug	Vial/Amp (Storage)	Route	Vial Reconstitution	Vial Final Conc.	VIAL BUD	Further Dilution	BUD REF	BUD RT	Infusion Rate	Comments
MitoMYCIN (Mutamycin) ***NOTE: U-LISTED**	5 mg 20 mg 40 mg (RT;PFL)	IV	SWFI: 5 mg: 10 mL 20 mg: 40 mL	0.5 mg/mL	6 hr PFL	N/A <i>Dispense in syringe</i> <i>May dilute in NS to 20-40 mcg/mL</i>	14 d PFL	7 d PFL <i>Diluted 12 hr</i>	IVP over 10 – 15 min	VESICANT Max syringe volume: 22.5 mL in 30 mL syringe EP: Low
		IRR/ Intrav esical	20 mg: NS 20 mL 40 mg: NS 40 mL	1 mg/mL		N/A <i>Dispense in slip-tip (catheter) syringe</i>	N/A	24 hr	Bladder dwell (max 2 hrs)	
Mycophenolate (Cellcept)	500 mg (RT)	IV	D5W: 14 mL	33.3 mg/mL	4 hr	D5W to 6 mg/mL 500 mg: 85 mL 1000 mg: 140 mL 1500 mg: 210 mL		4 hr	2 hr	
Natalizumab (Tysabri) - criteria <i>Restricted to neurology</i>	300 mg (REF;PFL)	IV	Solution	20 mg/mL	N/A Discard Unused	NS 100 mL	8 hr	Imme diate	60 min	DO NOT SHAKE May warm to RT prior to admin
Nivolumab (Opdivo)	40 mg 100 mg (REF; PFL)	IV	Solution	10 mg/mL	N/A Discard Unused	Add drug to empty container and then further dilute with NS to final conc of 1-10 mg/mL <i>Alternative: D5W</i>	24 hr	4 hr	30 min	DO NOT SHAKE Tubing: 0.2 micron low protein binding in-line filter (10010454) 0.2-1.2 micron filter EP: Minimal
OBINutuzumab (Gazyva)	1 gram (REF;PFL)	IV	Solution	25 mg/mL	N/A Discard Unused	NS 100 mg: 100 mL 900 mg: 250 mL 1 gram: 250 mL <i>NS ONLY</i>	72 hr (24 hr REF then 48 hr RT)	48 hr	Titrated – see PI	DO NOT SHAKE Use dilution to prime line • Premedication: ○ First dose: acetaminophen, diphenhydramine, decadron ○ Subsequent doses: acetaminophen +/- diphenhydramine +/- decadron • EP: Minimal

PFL=protect from light; BUD=Beyond Use Date; REF=refrigeration; RT=room temperature; SWFI=sterile water for injection (preservative free);

SubQ=subcutaneous; IM=intramuscular; BWFI=bacteriostatic water for injection ; NS=0.9% saline solution; D5W=dextrose 5% in water; LR=lactated ringers solution;

EP: Emetogenic Potential; SDV: single-dose vial; MDV: multi-dose vial; **Use secondary tubing unless otherwise specified.**

*multi-dose vial

vAug2018-BF

Page 10 of 16



OVAMC Pharmacy Services – Chemotherapy/Hazardous Medication Dilution Chart

****All products should have the following stickers at minimum: BUD, Chemo or Hazardous, REF or Room Temp****

Drug	Vial/Amp (Storage)	Route	Vial Reconstitution	Vial Final Conc.	VIAL BUD	Further Dilution	BUD REF	BUD RT	Infusion Rate	Comments
Ocrelizumab (Ocrevus) (hazardous-not chemo)	300mg (REF;PFL)	IV	Solution	30mg/mL	6 hr REF	NS 300mg: 250mL 600mg: 500mL NS ONLY	24 hr	8 hr	SEE FOOTNOTES Max: 200mg/hr	DO NOT SHAKE Tubing: 0.2 micron low protein binding in-line filter (10010454) <u>Do not use</u> if discrete particles or discolored;
OFATumumab (Arzerra)	100mg 1 gram (REF;PFL)	IV	Solution	20 mg/mL	N/A Discard Unused	NS 1000 mL Withdraw volume from bag equal to drug volume to be added prior to dilution	24 hr	24 hr	Titrated – see PI Begin within 12 hrs of prep	DO NOT SHAKE Use dilution to prime line Use supplied in-line set • Premedication: acetaminophen, diphenhydramine, corticosteroid • EP: Minimal
Omacetaxine Mepesuccinate (Synribo)	3.5 mg (RT;PFL)	SubQ	NS 1 mL	3.5 mg/mL	6 hr RT;PFL	N/A	N/A	N/A	SubQ ONLY	EP: Low
Oxaliplatin (Eloxatin)	50 mg 100 mg 200 mg (RT;PFL)	IV	Solution	5 mg/mL	6 hr RT	D5W 500 mL D5W ONLY	24 hr	6 hr	120 min	VESICANT Tubing: primary (2420-0500) EP: Moderate
PAClitaxel (Taxol) *Not interchangeable with paclitaxel protein bound- albumin	100 mg* 300 mg* (RT;PFL)	IV	Solution	6 mg/mL	MDV: 28 day RT	NS <300mg: 250 mL ≥300 mg: 500 mL Final conc: 0.3-1.2 mg/mL Alt: D5W		72 hr	<100 mg/m ² 60 min ≥100 mg/m ² 3 hours May be given as continuous infusion	IRRITANT Use DEHP-free bags/device Tubing: 0.2 micron low protein binding in-line filter (10010454) • Premedication: H2 antagonist, diphenhydramine, and dexamethasone • EP: Low
PAClitaxel plasma protein bound-albumin (Abraxane) *NOT interchangeable w/ paclitaxel	100 mg (RT;PFL)	IV	NS 20 mL Direct diluent down side of vial over ≥1 min	5 mg/mL	6 hr REF	DO NOT DILUTE Place in empty bag	24 hr PFL	8 hr	30 min	DO NOT SHAKE DO NOT FILTER EP: Low

PFL=protect from light; BUD=Beyond Use Date; REF=refrigeration; RT=room temperature; SWFI=sterile water for injection (preservative free);

*multi-dose vial

vAug2018-BF

SubQ=subcutaneous; IM=intramuscular; BWFI=bacteriostatic water for injection ; NS=0.9% saline solution; D5W=dextrose 5% in water; LR=lactated ringers solution;

Page 11 of 16

EP: Emetogenic Potential; SDV: single-dose vial; MDV: multi-dose vial; Use secondary tubing unless otherwise specified.



OVAMC Pharmacy Services – Chemotherapy/Hazardous Medication Dilution Chart

****All products should have the following stickers at minimum: BUD, Chemo or Hazardous, REF or Room Temp****

Drug	Vial/Amp (Storage)	Route	Vial Reconstitution	Vial Final Conc.	VIAL BUD	Further Dilution	BUD REF	BUD RT	Infusion Rate	Comments
Pamidronate (Aredia)	30mg 60mg 90mg (RT)	IV	SWFI 10 mL	Varies	6 hr	NS 500 mL <i>Alternative: D5W</i>		24 hr	2 hr	Monitor Ca May be infused over 2-24 hrs
Panitumumab (Vectibix) (hazardous-not chemo)	100 mg 400 mg (REF;PFL)	IV	Solution	20 mg/mL	N/A Discard Unused	NS ONLY ≤ 1 gram: 100 mL > 1 gram: 150 mL Final conc: ≤ 10 mg/mL	24 hr	6 hr	≤ 1 gram: 60 min > 1 gram: 90 min	DO NOT SHAKE Tubing: 0.2 micron low protein binding in-line filter (10010454) <ul style="list-style-type: none">• Monitor magnesium• EP: Minimal
Pembrolizumab (Keytruda)	50 mg (REF)	IV	SWFI 2.3 mL <i>Direct diluent down side of vial slowly</i>	25 mg/mL	4 hr RT 6 hr REF	NS 50 mL Final conc: 1 – 10 mg/mL <i>NS ONLY</i>	24 hr	4 hr	30 min	DO NOT SHAKE Use 0.2 - 5 micron low protein in-line filter EP: Minimal
Pemetrexed (Alimta)	100 mg 500 mg (RT)	IV	NS 100 mg: 4.2 mL 500 mg: 20 mL	25 mg/mL	6 hrs	NS 100 mL <i>Alternative: D5W</i>	24 hr	24 hr	10 min	Solution may be colorless, yellow or yellow-green Tubing: secondary (MS3500-15) <ul style="list-style-type: none">• Vitamin B₁₂ and folic acid supplementation routinely started 1 week prior to first dose• Dexamethasone should be started the day before to decrease rash• EP: Low
Pentamidine	300 mg (RT;PFL)	IV	SWFI 5 mL	60 mg/mL	48 hrs RT;PFL	D5W ≤250 mg: 100 mL >250 mg: 250 mL Final Conc: ≤2.5 mg/mL		24 hrs PFL	60 min	Usual dose: 4 mg/kg Incompatible with NS Avoid extravasation
Pertuzumab (Perjeta)	420 mg (REF;PFL)	IV	Solution	30 mg/mL	N/A Discard Unused	NS 250 mL <i>NS ONLY</i>	24 hr	4 hr	Load: 60min Maint.: 30 min	DO NOT SHAKE EP: Minimal

PFL=protect from light; BUD=Beyond Use Date; REF=refrigeration; RT=room temperature; SWFI=sterile water for injection (preservative free);
SubQ=subcutaneous; IM=intramuscular; BWFI=bacteriostatic water for injection ; NS=0.9% saline solution; D5W=dextrose 5% in water; LR=lactated ringers solution;
EP: Emetogenic Potential; SDV: single-dose vial; MDV: multi-dose vial; **Use secondary tubing unless otherwise specified.**



OVAMC Pharmacy Services – Chemotherapy/Hazardous Medication Dilution Chart

****All products should have the following stickers at minimum: BUD, Chemo or Hazardous, REF or Room Temp****

Drug	Vial/Amp (Storage)	Route	Vial Reconstitution	Vial Final Conc.	VIAL BUD	Further Dilution	BUD REF	BUD RT	Infusion Rate	Comments
Ramucirumab (Cyramza)	100 mg 500 mg (REF; PFL)	IV	Solution	10 mg/mL	N/A Discard Unused	NS 250 mL <i>Total volume</i> <i>NS ONLY</i>	24 hr	4 hr	60 min	DO NOT SHAKE 0.22 micron filter <ul style="list-style-type: none"> • Monitor urine for protein • Premedication: diphenhydramine <ul style="list-style-type: none"> ○ If prior reaction, add dexamethasone and acetaminophen • EP: Minimal
Rituximab (Rituxan) (hazardous-not chemo) (restricted - Onc) (criteria – Rheum)	100 mg 500 mg (REF;PFL)	IV	Solution	10 mg/mL	6 hrs	First/subsequent NS QS to final conc of 1 mg/mL Rapid infusion: NS 500 mL <i>Alternative: D5W</i>	24 hrs + additi onal 24 hours at RT	24 hrs	SEE FOOTNOTES Max: 400mg/hr	DO NOT SHAKE Hypersensitivity risk Tubing: primary (2420-0500) EP: Minimal
RomiDEPsin (Istodex)	10 mg (RT)	IV	Supplied diluent 2 mL	5 mg/mL	6 hr RT	NS 500 mL		24 hr	4 hr	<ul style="list-style-type: none"> • Baseline and periodic EKG monitoring recommended – known to cause QTc prolongation • Monitor K, Mg, Phos • EP: Low
Tacrolimus DRIP	5 mg (RT)	IV	Solution	5 mg/mL	6 hr	NS QS to final conc Final Conc: 4-20 mcg/mL <i>Alternative: D5W</i>		24 hrs	Continuous infusion	Use DEHP free bags Hypersensitivity risk
Temsirolimus (Torisel)	25 mg (REF;PFL)	IV	Provided diluent: 1.8 mL Protect from light during all steps	10 mg/mL	6 hr RT	NS 250 mL		6 hrs PFL	30-60 min	DO NOT SHAKE Use DEHP free bags/tubing Use 5 micron in-line filter Hypersensitivity risk <ul style="list-style-type: none"> • Premedication: Diphenhydramine • EP: Minimal

PFL=protect from light; BUD=Beyond Use Date; REF=refrigeration; RT=room temperature; SWFI=sterile water for injection (preservative free);

SubQ=subcutaneous; IM=intramuscular; BWFI=bacteriostatic water for injection ; NS=0.9% saline solution; D5W=dextrose 5% in water; LR=lactated ringers solution;

EP: Emetogenic Potential; SDV: single-dose vial; MDV: multi-dose vial; **Use secondary tubing unless otherwise specified.**

*multi-dose vial

vAug2018-BF

Page 13 of 16



Defining
EXCELLENCE
in the 21st Century

OVAMC Pharmacy Services – Chemotherapy/Hazardous Medication Dilution Chart

****All products should have the following stickers at minimum: BUD, Chemo or Hazardous, REF or Room Temp****

Drug	Vial/Amp (Storage)	Route	Vial Reconstitution	Vial Final Conc.	VIAL BUD	Further Dilution	BUD REF	BUD RT	Infusion Rate	Comments
Tocilizumab (Actemra)	80mg 200mg 400mg (REF;PFL)	IV	Solution	20 mg/mL	24 hr REF	NS 100 mL	24 hrs PFL	24 hrs PFL	60min	DO NOT SHAKE
Topotecan (Hycamtin)	4 mg (Solution: RT;PFL) (Powder: REF, PFL)	IV	Powder: SWFI 4 mL	1 mg/mL	6 hr RT	NS 100 mL <i>Alternative: D5W</i>	7 days	24 hr	30 min	EP: Low
Trastuzumab (Herceptin) (hazardous-not chemo)	150mg (REF)	IV	SWFI 7.4mL	21 mg/mL	SDV: 24 hrs REF	NS 250 mL <i>NS ONLY</i>	24 hr		Initial: 90 min Maint: 30 min	DO NOT SHAKE Tubing: secondary (MS3500-15) Baseline and periodic LVEF required EP: Minimal
Valproate sodium (non-form) (hazardous-not chemo)	500mg (RT)	IV	Solution	100mg/mL	6 hr	50 mL NS <i>Alternative: D5W</i>		24 hr	60min	Dose: 5-15mg/kg/day
Valrubicin (Valstar)	200 mg (REF; PFL)	Intrav esical	Solution	40 mg/mL	N/A	Dilute with 55mL NS for total volume of 75 mL		12 hr	Dwell time: 2 hours	Use non-DEHP containing devices
Vedolizumab (Entyvio) (hazardous-not chemo)	300mg (REF;PFL)	IV	SWFI 4.8mL	60 mg/mL	4hr REF	NS 250mL	4 hr		30 min	DO NOT SHAKE
VinBLASTine (Velban)	10 mg (REF;PFL)	IV	NS 10 mL -or- Solution	1 mg/mL	6 hr	NS 50 mL <i>Alternative: D5W</i>	24 hr	24 hr	10 min <i>Peripheral line: infuse via gravity</i>	VESICANT NEVER INTRATHECAL (fatal) EP: Minimal
VinCRISTine (Oncovin; Vincasar)	1 mg 2 mg (REF;PFL)	IV	Solution	1 mg/mL	24 hr REF	NS 50 mL <i>Alternative: D5W</i>	7 days	48 hr	10 min <i>Peripheral line: infuse via gravity</i>	VESICANT NEVER INTRATHECAL (fatal) Tubing: secondary (MS3500-15) EP: Minimal

PFL=protect from light; BUD=Beyond Use Date; REF=refrigeration; RT=room temperature; SWFI=sterile water for injection (preservative free);

SubQ=subcutaneous; IM=intramuscular; BWFI=bacteriostatic water for injection ; NS=0.9% saline solution; D5W=dextrose 5% in water; LR=lactated ringers solution;

EP: Emetogenic Potential; SDV: single-dose vial; MDV: multi-dose vial; **Use secondary tubing unless otherwise specified.**

*multi-dose vial

vAug2018-BF

Page 14 of 16



OVAMC Pharmacy Services – Chemotherapy/Hazardous Medication Dilution Chart

****All products should have the following stickers at minimum: BUD, Chemo or Hazardous, REF or Room Temp****

Drug	Vial/Amp (Storage)	Route	Vial Reconstitution	Vial Final Conc.	VIAL BUD	Further Dilution	BUD REF	BUD RT	Infusion Rate	Comments
VinORELBine (Navelbine)	10 mg 50 mg (REF;PFL)	IV	Solution	10 mg/mL	6 hr	NS 50 mL (0.5-2 mg/mL) <i>Alternative: D5W</i>		24 hr	10 min <i>Peripheral line: infuse via gravity</i>	IRRITANT NEVER INTRATHECAL (fatal) Tubing: secondary (MS3500-15) EP: Minimal
ZIV-aflibercept (Zaltrap)	100 mg 200 mg (REF;PFL)	IV	Solution	25 mg/mL	6 hr	NS QS to final conc Final Conc: 0.6 – 8 mg/mL <i>Alternative: D5W</i>	24 hr	4 hr	60 min	Infuse with 0.2 micron polyethersulfone filter Tubing: primary (2420-0500)
Zoledronic acid (Zometa, Reclast) – criteria (hazardous-not chemo)	Premix: 4 mg 5mg (RT) Vial: 4 mg 5 mg (RT)	IV	Premix (100 mL) -or- SWFI: 5 mL	Varies	Premix N/A Vial: 6 hrs	Premix: none (0.04-0.05 mg/mL) Vial: 100 mL NS <i>Alternative: D5W</i>	24 hrs		15 min	Monitor Ca

PFL=protect from light; BUD=Beyond Use Date; REF=refrigeration; RT=room temperature; SWFI=sterile water for injection (preservative free);

*multi-dose vial

SubQ=subcutaneous; IM=intramuscular; BWFI=bacteriostatic water for injection ; NS=0.9% saline solution; D5W=dextrose 5% in water; LR=lactated ringers solution;

EP: Emetogenic Potential; SDV: single-dose vial; MDV: multi-dose vial; **Use secondary tubing unless otherwise specified.**

vAug2018-BF

Page 15 of 16



OVAMC Pharmacy Services – Chemotherapy/Hazardous Medication Dilution Chart

****All products should have the following stickers at minimum: BUD, Chemo or Hazardous, REF or Room Temp****

Daratumumab infusions:

- **First infusion:** total dose (16mg/kg) divided between day 1 and day 2 (8mg/kg each day in 500mL NS); begin infusion at 50ml/hr; increase by 50ml/hr every hour to maximum of 200ml/hr.
- **Second infusion:** mix in 500mL; begin infusion at 50ml/hr; increase by 50ml/hr every hour to maximum of 200ml/hr.
- **Subsequent infusions:** mix in 500mL; begin infusion at 100m/hr; increase by 50ml/hr every hour to maximum of 200ml/hr

Ocrelizumab infusions:

- **300mg:** begin infusion at 30mL/hr; increase by 30mL/hr every 30 minutes to maximum of 180mL/hr [duration 2.5 hours or LONGER]
- **600mg:** begin infusion at 40mL/hr; increase by 40mL/hr every 30 minutes to maximum of 200mL/hr [duration 3.5 hours or LONGER]

Rituximab infusions:

- **First infusion:** In equal volume of NS (1mg/ml); Begin infusion at 50ml/hr; increase by 50ml/hr every 30 minutes to maximum of 400ml/hr.
- **Rapid infusion (only if tolerated first infusion):** In NS 500ml; initiate infusion at 200ml/hr for 30 minutes; if patient tolerates, infuse the remaining 400ml over 1 hour.
- **Subsequent infusions, not rapid infusion:** In equal volume of NS (1mg/ml); Begin infusion at 100ml/hr; increase by 100mg/hr every 30 minutes to maximum of 400ml/hr.